OUR PRODUCTS
Each non-dispersible tablet contains Montelukast Sodium IP equivalent to 4 mg Montelukast and 2.5 mg Levocetirizine Hydrochloride.
- Do not use Levokast in patients with known hypersensitivity to montelukast, levocetirizine, or cetirizine, or to any of the excipients. Observed reactions range from urticaria to anaphylaxis.
- End-stage renal disease with less than 10 ml/min creatinine clearance, in patients undergoing hemodialysis.
- Patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose deficiency.
- Phenobarbital, phenytoin, rifampicin: Decreased plasma concentrations of montelukast.
- Theophylline: a slight decrease in the clearance of cetirizine.
- Ritonavir: increased plasma concentration of cetirizine
- Alcohol and nervous system depressants: Increased effect on the central nervous system.
- Asthma
- Alleviation of symptoms of allergic rhinitis (seasonal and permanent).
Dosage :
- One tablet once daily by mouth.
- The elderly and patients with renal or hepatic impairment: No dose adjustment is required in the elderly and patients with hepatic insufficiency, while close monitoring and possible dose adjustment in patients with renal insufficiency
Abdominal pain, asthenia, diarrhea, headache, pharyngitis, otitis media, indigestion, gastroenteritis, influenza, nasal congestion, skin rashes, increased liver enzymes, thrombocytopenia, aggression, anxiety, depression, drowsiness, numbness, palpitations, Pancreatitis, angioedema, arthralgia, myalgia, enuresis in children.....
LEVOKAST dispersible tablets ............
A carton box containing one blister with 10 dispersible tablets